OncoMatch/Clinical Trials/NCT04162353
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Is NCT04162353 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BCMA-CD19 cCAR T cells for multiple myeloma in relapse.
Treatment: BCMA-CD19 cCAR T cells — This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: standard therapeutic options
Patients have exhausted standard therapeutic options
Cannot have received: BCMAxCD3 or CD19xCD3 bispecific antibody
Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
Cannot have received: solid organ transplantation
Prior solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04162353 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCMAxCD3 or CD19xCD3 bispecific antibody, solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages